欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (7): 961-967.doi: 10.12092/j.issn.1009-2501.2025.07.011

• 综述与讲座 • 上一篇    下一篇

真性红细胞增多症治疗新进展

李玥明,张永超,陈芳   

  1. 中国医科大学附属盛京医院血液研究室,沈阳  110004,辽宁
  • 收稿日期:2024-09-06 修回日期:2025-01-03 出版日期:2025-07-26 发布日期:2025-07-02
  • 通讯作者: 陈芳,女,博士,副教授/副主任医师,研究方向:骨髓增殖性肿瘤,骨髓瘤。 E-mail: 18940255342@163.com
  • 作者简介:李玥明,女,研究方向:骨髓增殖性肿瘤。 E-mail: liyueming198993@163.com
  • 基金资助:
    国家自然科学基金青年基金(82200227)

New progress in the treatment of polycythemia vera 

LI Yueming, ZHANG Yongchao, CHEN Fang   

  1. Department of Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
  • Received:2024-09-06 Revised:2025-01-03 Online:2025-07-26 Published:2025-07-02

摘要:

真性红细胞增多症(polycythemia vera,PV)属于BCR::ABL1阴性骨髓增殖性肿瘤(myeloproliferative neoplasms,MPN)的一种,是由造血干细胞中的基因突变引发的慢性髓系肿瘤。PV具有一定的进展为骨髓纤维化或急性髓系白血病的风险。目前,治疗PV的目标仍然是预防血栓形成,随着对PV研究的不断深入,使得以往的以减轻患者症状的终身治疗向阻止疾病进展的限时治疗转变成为可能。本文将对传统减细胞治疗药物的作用机制及最新临床试验结果,以及PV新药和联合用药的早期临床试验数据及其作用机制进行综述,以期为关注PV治疗的研究者们提供帮助。

关键词: 真性红细胞增多症, 芦可替尼, 干扰素

Abstract:

Polycythemia vera (PV) is a type of BCR::ABL1 negative myeloproliferative neoplasms (MPN), which is a chronic myeloid tumor caused by gene mutations in hematopoietic stem cells. PV has a certain risk of progressing to myelofibrosis or acute myeloid leukemia. At present, the goal of PV treatment is still to prevent thrombosis. With the deepening of PV research, it is possible to transform the lifelong treatment to prevent the progression of the disease from alleviating the symptoms of patients. This article reviews the mechanism of traditional cytoreductive therapy drugs and the latest clinical trial results, as well as the early clinical trial data and their mechanism of action of new PV drugs and combination of drugs, in order to provide help for researchers who pay attention to PV treatment.

Key words: polycythemia vera, Ruxolitinib, Interferon

中图分类号: